Omalizumab, the first approved anti‐IgE antibody, could effectively neutralize serum IgE regardless of allergen specificity, decrease FcεRI expression on mast cells, basophils, and dendritic cells, inhibiting FcεRI mediated allergic diseases and further reduce the risk of exacerbations.13 Here, IGHE is linked to allergic disease.